| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Swiss Institute for Experimental Cancer Research, National Center of Competence in Research Molecular Oncology, Epalinges, Switzerland; and
National Institute for Medical Research, The Ridgeway, London, United Kingdom
Human T lymphocytes can be numerically expanded in vitro only to a limited extent. The cyclin-dependent kinase inhibitor p16INK4a is essential in the control of cellular proliferation, and its expression, in epithelial cells, is associated with irreversible growth arrest. Using long-term cultured CD8+ T lymphocytes, we have investigated the role of the p16/pRb pathway in the regulation of T cell proliferation and senescence. In this study, we describe at least two mechanisms that cause replicative growth arrest in cultured lymphocytes. The first one depends on the expression of p16INK4a and is directly responsible for the exit of a significant proportion of CD8+ T cells from the proliferative population. This induced p16 expression pattern is observed during each round of mitogen stimulation and is not related to activation-induced cell death. Importantly, knocking down p16INK4a expression allows increased proliferation of T cells. The second one is a phenomenon that resembles human fibroblast senescence, but is independent of p16INK4a and of telomere attrition. Interestingly, virtually all pRb proteins in the senescent population are found in the active form. Our data indicate that newly synthesized p16INK4a limits the proliferation of T lymphocytes that respond to mitogen, but is not required for the loss of mitogen responsiveness called senescence.
This article has been cited by other articles:
|
|
 |
|
  M. L. Turner, E. D. Hawkins, and P. D. Hodgkin Quantitative Regulation of B Cell Division Destiny by Signal Strength J. Immunol., July 1, 2008; 181(1): 374 - 382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. L. Montes, A. I. Chapoval, J. Nelson, V. Orhue, X. Zhang, D. H. Schulze, S. E. Strome, and B. R. Gastman Tumor-Induced Senescent T Cells with Suppressor Function: A Potential Form of Tumor Immune Evasion Cancer Res., February 1, 2008; 68(3): 870 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. H. Lemster, J. J. Michel, D. T. Montag, J. J. Paat, S. A. Studenski, A. B. Newman, and A. N. Vallejo Induction of CD56 and TCR-Independent Activation of T Cells with Aging J. Immunol., February 1, 2008; 180(3): 1979 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Fosmire, R. Thomas, C. M. Jubala, J. W. Wojcieszyn, V. E. O. Valli, D. M. Getzy, T. L. Smith, L. A. Gardner, M. G. Ritt, J. S. Bell, et al. Inactivation of the p16 Cyclin-Dependent Kinase Inhibitor in High-Grade Canine Non-Hodgkin's T-Cell Lymphoma Vet. Pathol., July 1, 2007; 44(4): 467 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Menzel, M. Migliaccio, D. R. Goldstein, S. Dahoun, M. Delorenzi, and N. Rufer Mechanisms Regulating the Proliferative Potential of Human CD8+ T Lymphocytes Overexpressing Telomerase J. Immunol., September 15, 2006; 177(6): 3657 - 3668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Schmid, J. P. H. Depta, M. Luthi, and W. J. Pichler Transfection of Drug-Specific T-Cell Receptors into Hybridoma Cells: Tools to Monitor Drug Interaction with T-Cell Receptors and Evaluate Cross-Reactivity to Related Compounds Mol. Pharmacol., July 1, 2006; 70(1): 356 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Migliaccio, P. M. S. Alves, P. Romero, and N. Rufer Distinct Mechanisms Control Human Naive and Antigen-Experienced CD8+ T Lymphocyte Proliferation J. Immunol., February 15, 2006; 176(4): 2173 - 2182. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
